Previous 10 | Next 10 |
2023-08-28 15:12:12 ET If you’re looking to gain an edge in the stock market today, you’ve got to have more than a list of penny stocks to watch. You need to understand how to use the wild volatility that has been created this year to your advantage. Whether there’s...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a f...
2023-08-10 17:18:45 ET Xeris Pharmaceuticals press release ( NASDAQ: XERS ): Q2 revenue of $38M (+50.1% Y/Y) misses by $2.93M . For further details see: Xeris Pharmaceuticals reports Q2 revenue
--News Direct-- Xeris Biopharma chairman and CEO Paul Edick joined Proactive's Stephen Gunnion with details of the company's second-quarter performance, which saw record revenue driven by the success of their products, including Gvoke, Keveyis, and Recorlev. For the quarter, which end...
2023-08-08 11:55:02 ET Xeris Biopharma Holdings, Inc. (XERS) Q2 2023 Results Conference Call August 08, 2023 08:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations Paul Edick - Chairman and Chief Executive Officer Steven P...
Dallas, Texas--(Newsfile Corp. - August 8, 2023) - Stonegate is pleased to announce the release of a thematic report that examines small market cap pharmaceutical companies based on revenue growth and valuation. The report: Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline ex...
2023-08-08 07:06:57 ET Xeris Pharmaceuticals press release ( NASDAQ: XERS ): Q2 GAAP EPS of -$0.14 misses by $0.01 . Revenue of $38.01M (+50.2% Y/Y) beats by $3.17M . “We posted another record quarter of revenue due to the continued strong demand of all ...
Achieved record revenue of $38.0M – a 14% increase from prior quarter, and a 50% increase from same period prior year Ended Q2 with over $80M in cash, cash equivalents and short-term investments Tightens full-year 2023 guidance: total net revenue of $145M-$165M; cash utiliz...
2023-08-07 13:39:24 ET Xeris Pharmaceuticals ( NASDAQ: XERS ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, before market open. The consensus EPS Estimate is -$0.11 and the consensus Revenue Estimate is $34.84M (+37.7% Y/Y). Over the last 2 years...
Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the C...
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track reco...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2024, the Compensation Committee of Xeris’ Boar...
In patients with Cushing’s syndrome maintained on Recorlev, a lower baseline mUFC was associated with higher cortisol normalization rate. Lower mUFC at baseline was also associated with lower maintenance dose requirements and lower rates of potentially clinically important liver-re...